HEALTHCARE
Amanta Healthcare shares to list tomorrow. Here's what GMP indicates ahead of debut
Amanta Healthcare, an Ahmedabad-based pharmaceutical company, is set to debut on the market with modest expectations, indicated by a GMP of 7%. The IPO, which closed on September 3rd, saw the company issue fresh shares to fund expansion, including a new SteriPort manufacturing line.
AstraZeneca to invest Rs 176 cr to expand GITC in Chennai
AstraZeneca is investing Rs 176 crore to expand its Global Innovation & Technology Centre in Chennai, marking its third investment in India in two years. This expansion will enhance the center's capabilities in AI, data analytics, and machine learning, supporting the development of next-generation medicines and digital healthcare solutions.
Pharma sector hails GST cut as a landmark move toward affordable healthcare
GST rates on 33 life-saving drugs have been reduced to zero, while rates on other medicines and diagnostics have been cut to 5%. The industry welcomes the reform as a major relief for patients.
US firm to launch 'revolutionary' portable AI ultrasound device in Bangladesh
Exo Imaging, a US-based company, plans to introduce its AI-powered portable ultrasound device in Bangladesh, marking its first Asian deployment. The device, already FDA-approved in the US, promises to revolutionize healthcare access, especially in rural areas, by enabling early detection of various conditions. This initiative aims to bring diagnostics closer to patients, reducing wait times and improving healthcare delivery.
Sansum Clinic healthcare workers in Santa Barbara mock patients in viral video. This is what happened next
Sansum Clinic healthcare workers in Santa Barbara mock patients in viral video shared by an ex-employee. Sutter Health confirmed the workers were fired, sparking public outrage and negative reviews for the clinic.
GST rate cuts complement Ayushman Bharat, PMJAY, says health ministry
The government's GST reforms aim to make healthcare more accessible and affordable by exempting health and life insurance premiums, reducing taxes on essential medicines and medical products. These changes complement initiatives like Ayushman Bharat and PMJAY, encouraging wider insurance adoption and lowering healthcare costs for citizens. The move also supports preventive healthcare by maintaining high taxes on harmful goods.
- Go To Page 1
GST cut on drugs, medical devices to provide relief to patients: Industry players
The government is reducing GST on medicines and medical devices. Lifesaving drugs are exempt. This action will help patients and families. It will also make healthcare more affordable. Sudarshan Jain and Anil Matai welcome the changes. Ameera Shah and Shobana Kamineni also support the move. Himanshu Baid says it will improve access to medical technologies.
AI-led healthcare startup Reveal HealthTech raises $7.2 million in round led by Leo Capital
Sanos Capital participated in the funding round. Reveal was incubated by W Health Ventures, which supports startups in the US and India that focus on improving care delivery by leveraging technology. The US-headquartered startup will use the funds to scale its flagship products — BioCanvas, which applies multimodal AI to accelerate clinical trial recruitment, and Prism AI, a workflow automation platform.
Amanta Healthcare IPO allotment likely out today: Follow these steps to check status, GMP
Amanta Healthcare's Rs 126 crore IPO allotment is finalized today, following an overwhelming 82.60 times subscription. Shares will be credited to demat accounts on September 5, with BSE and NSE listing scheduled for September 8. Investors can check allotment status via MUFG Intime India or the BSE IPO allotment page.
Put more money where healthcare is
India's health insurance sector has surpassed ₹1 lakh crore in premiums, but a concerning trend emerges as insurers prioritize cost containment over operational efficiency. They are pressuring healthcare providers to cut costs, leading to delayed payments and compromised clinical decisions.
Woman bitten by spider turns to ChatGPT for help, and doctors say it saved her life
A Texas woman credited ChatGPT with prompting her to seek urgent care after a spider bite turned dangerous, according to Mirror. Holli, a TikTok user, described severe symptoms including vomiting and numbness before the AI advised her to go to hospital, where doctors confirmed tissue damage. Her case reignites debate on AI in healthcare, with experts warning chatbots can’t replace medical professionals, though they may sometimes encourage timely action.
Amanta Healthcare IPO subscribed nearly 83 times at close; GMP at 8%. Should you bid?
Amanta Healthcare’s Rs 126 crore IPO was subscribed nearly 83 times at close, driven by NIIs and RIIs. Trading at an 8% GMP, the stock may list around Rs 136. The company’s sterile liquid pharmaceuticals focus and global certifications position it for strong growth.
Anlon Healthcare shares make a tepid debut. Should IPO investors wait or sell?
Anlon Healthcare’s shares debuted with a modest 1% premium amid volatile pharma markets, despite a strong 7.12x IPO subscription driven by retail investors. The specialized API manufacturer showed robust financial growth, with revenue up 81% in FY25 and expanding profit margins. While niche products and global approvals boost prospects, risks include limited operating history and regulatory challenges. Analysts consider the IPO fully priced.
Anlon Healthcare shares make a muted D-Street debut, shares list at 1% premium over IPO price
Anlon Healthcare shares had a muted debut, listing slightly above its IPO price after a nearly 7x subscription. The company plans to use the Rs 121 crore raised for expansion and debt reduction. Despite a limited operating history and regulatory risks, Anlon's strong financial growth, expanding product portfolio, and regulatory approvals make it a compelling long-term investment.
Amanta Healthcare IPO subscribed 12.40 times on Day 2; GMP at 12% — Should you bid? Check key details
Amanta Healthcare's Rs 126 crore IPO witnessed strong investor demand, subscribing 12.40 times on its second day, driven by retail investors. The IPO, closing on September 3, sees shares trading at a 12% grey market premium. The Ahmedabad-based pharmaceutical firm plans to use IPO proceeds for expansion. Investor4Edu recommends subscribing, citing growth potential in sterile pharmaceuticals.
Anlon Healthcare IPO GMP: Will healthy subscription lead to a strong listing tomorrow?
Anlon Healthcare, a Gujarat-based API and pharma intermediates manufacturer, will debut on the stock exchanges on Wednesday after its Rs 121 crore IPO was subscribed nearly 7 times. Despite strong fundamentals and capacity expansion plans, the grey market premium suggests muted listing gains. Analysts remain optimistic about its long-term growth potential amid rising demand and the “China + 1” supply shift.
Fortis Healthcare arm inks 15-year lease with RR Lifesciences to expand NCR reach
Fortis Healthcare's subsidiary, International Hospital Limited, has secured a 15-year lease. This agreement with RR Lifesciences Limited allows Fortis to operate and expand its facility in Greater Noida. Fortis will now have complete control over the 200-bed hospital, known as Fortis Hospital Greater Noida. The hospital aims to increase its capacity to approximately 250 beds.
Not just AI jobs: These 10 professions are set to see strong growth in next 10 years, says US labor bureau
The U.S. Bureau of Labor Statistics projects 5.2 million new jobs by 2034, bringing total employment to 175.2 million, though growth will be slower than the past decade. Healthcare and social assistance lead with 8.4 percent growth, driven by aging populations and chronic illness. AI will both create demand for data scientists and cybersecurity experts while displacing office and production roles. Renewable energy and social services also emerge as key growth areas, highlighting a nuanced future of work.
Amanta Healthcare IPO subscribed 3.2 times so far on Day 1; GMP at 15%. Should you bid?
Amanta Healthcare's IPO witnessed strong investor demand, being oversubscribed 3.2 times on its opening day, driven by retail and non-institutional investors. The IPO, a fresh issue of 1 crore shares, is trading at a 15% premium in the grey market, signaling potential listing gains. The company plans to use the IPO proceeds for expansion and general corporate purposes.
Novo Nordisk ties up with Apollo Clinics for obesity management initiative
Novo Nordisk partners with Apollo Clinics to tackle obesity in India. The collaboration introduces a comprehensive obesity management programme across Indian cities. This initiative aims to provide structured care through multiple levels. The partnership focuses on equipping healthcare professionals with tools and support. The goal is to deliver personalized, evidence-based interventions.
European stocks rise as Novo Nordisk lifts healthcare on Wegovy data
Shares of Novo Nordisk, the fourth-largest healthcare company on the STOXX index, climbed 3.1% after the company said Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly's rival medicines Mounjaro and Zepbound in a real-world comparison.
Amanta Healthcare IPO opens for subscription; GMP at 22%. Should you bid?
IPO GMP: Amanta Healthcare's Rs 126 crore IPO opened on Monday, with a price band of Rs 120-126 per share. The Ahmedabad-based pharma company will use the funds to expand its manufacturing capabilities. Investor4Edu recommends subscribing, citing the company's strong position in the growing sterile liquid pharmaceuticals market. The IPO is valued at 47x post-issue FY25 earnings, with listing expected on September 8.
Anlon Healthcare IPO allotment likely today. Check GMP, status and other details
Anlon Healthcare has finalised its IPO share allotment. The IPO was subscribed 7.12 times. Retail portion saw heavy interest. Refunds will be processed on September 2. Successful applicants will receive shares in their demat accounts on the same day. Anlon Healthcare will list on September 3 on BSE and NSE.
ET Startup Awards 2025 | Top Innovator: Qure.ai bridges diagnostic gap
Founded in Mumbai in 2016 by Prashant Warier, Qure.ai’s mission is to make healthcare more affordable and accessible through AI-powered diagnostic tools. Its products assist clinicians in detecting conditions such as tuberculosis, lung cancer, and pulmonary disorders, speeding up diagnoses, and enabling more efficient treatment plans, particularly in resource-constrained settings.
Nita Ambani sheds light on key plans for Mumbai at the Reliance AGM 2025: A new medical city and a 130-acre green space
Reliance Foundation is set to develop a 2,000-bed medical city in Mumbai, featuring AI diagnostics and a teaching hospital, as announced by Nita Ambani. Simultaneously, the Foundation will develop a 130-acre green space with a public promenade, enhancing urban development and public access to open areas. These initiatives underscore Reliance's commitment to healthcare and sustainable urban development.
Anlon Healthcare IPO subscribed 3.8 times on Day 3 so far; GMP at 5%. Check details
Anlon Healthcare’s Rs 121 crore IPO drew robust demand, subscribed 3.8 times by Day 3, with retail investors leading at 25.85 times. Despite a modest 5% grey market premium, analysts back the issue for its strong product pipeline, global presence, and long-term growth prospects.
IHH Healthcare to add 2,000 beds in India by 2028
IHH Healthcare plans to expand its presence in India by adding approximately 2,000 new beds by 2028. This expansion will be facilitated through its subsidiaries, Fortis Healthcare and Gleneagles Healthcare, which currently operate 35 hospitals with over 5,000 beds across 11 states.
Anlon Healthcare IPO: Issue applied 184% on Day 2 so far; GMP at 4%. Should you subscribe?
Anlon Healthcare’s IPO is commanding a 4.4% grey market premium over its upper price band of ₹91, indicating a likely listing around ₹95 and hinting at modest debut gains.
Anlon Healthcare IPO subscribed 1.61 times on Day 1; GMP at 4%. Should you bid?
Anlon Healthcare's Rs 121 crore IPO opened with 5% subscription within the first hour, showing strong retail investor interest. The IPO, priced between Rs 86 and Rs 91, has a grey market premium of around 4%. Funds from the IPO will support expansion and debt repayment, with Anand Rathi recommending a 'Subscribe – Long Term' rating despite valuation concerns.
Load More
